Tamanoi Lab, iCeMS, Kyoto University

Welcome to Tamanoi Lab!

We research on nanoparticles and cancer therapy. Nanoparticles are attractive materials for delivery of anticancer drugs. We are focusing on mesoporous silica nanoparticles (MSN) that could contribute to prevention of side effect of cancer chemo therapy. MSN has a drug loading capacity and enables specific drug accumulation. We are also developing chicken egg tumor model.


Latest Publication

  • Higashi, Y., Ikeda, S., Matsumoto, K., Satoh, S., Komatsu, A., Sugiyama, H. and Tamanoi, F. (2022) Tumor Accumulation of PIP-Based KRAS Inhibitor KR12 Evaluated by the Use of a Simple, Versatile Chicken Egg Tumor Model. Cancers 2022, 14, 951. doi: 10.3390/cancers14040951

  • Komatsu, A., Matsumoto, K., Yoshimatsu, Y., Sin, Y., Kubota, A., Saito, T., Mizumoto, A., Ohashi, S., Muto, M., Noguchi, R., Kondo, T. and Tamanoi, F. (2021) The CAM Model for CIC-DUX4 Sarcoma and Its Potential Use for Precision Medicine. Cells. 10, 2613. doi: 10.3390/cells10102613.

  • Higashi, Y., Matsumoto, K., Saitoh, H., Shiro, A., Ma, Y., Laird, M., Chinnathambi, S., Birault, A., Doan, T.L.H., Yasuda, R., Tajima, T., Kawachi, T. and Tamanoi, F. (2021) Iodine containing porous organosilica nanoparticles trigger tumor spheroids destruction upon monochromatic X-ray irradiation: DNA breaks and K-edge energy X-ray. Sci. Rep. 11, 14192. doi: 10.1038/s41598-021-93429-9.

  • Gisbert-Garzarán, M., Lozano, D., Matsumoto, K., Komatsu, A., Manzano, M., Tamanoi, F. and Vallet-Regí, M. (2021) Designing Mesoporous Silica Nanoparticles to Overcome Biological Barriers by Incorporating Targeting and Endosomal Escape. ACS Appl Mater Interfaces 13, 9656-9666. doi: 10.1021/acsami.0c21507.

  • Tamanoi, F., Chinnathambi, S., Laird, M., Komatsu, A., Birault, A., Takata, T., Doan, T.L., Mai, N.X.D., Raitano, A., Morrison, K., Suzuki, M. and Matsumoto, K. (2021) Construction of Boronophenylalanine-Loaded Biodegradable Periodic Mesoporous Organosilica Nanoparticles for BNCT Cancer Therapy. Int. J. Mol. Sci. 22, 2251. doi: 10.3390/ijms22052251.

  • Chinnathambi, S. and Tamanoi, F. (2020) Recent Development to Explore the Use of Biodegradable Periodic Mesoporous Organosilica (BPMO) Nanomaterials for Cancer Therapy. Pharmaceutics. 12, 890. doi: 10.3390/pharmaceutics12090890.

  • Tamanoi, F., Matsumoto, K., Saitoh, H. and Shiro, A. (2020)「単色X 線とナノ粒子を組み合わせた新しいがん治療技術の開発にむけて」, Isotope News〔No.770〕2020年8月号, pp.7-11.

  • Tamanoi, F., Matsumoto, K., Doan, T.L.H., Shiro, A. and Saitoh, H. (2020) Studies on the Exposure of Gadolinium Containing Nanoparticles with Monochromatic X-rays Drive Advances in Radiation Therapy. Nanomaterials (Basel). 10, 1341. doi: 10.3390/nano10071341.

  • Mai, N.X.D., Birault, A., Matsumoto, K., Ta, H.K.T., Intasa-Ard, S.G., Morrison, K., Thang, P.B., Doan, T.L.H. and Tamanoi, F. (2020) Biodegradable Periodic Mesoporous Organosilica (BPMO) Loaded with Daunorubicin: A Promising Nanoparticle-Based Anticancer Drug. ChemMedChem. 15, 593-599. doi: 10.1002/cmdc.201900595.

Latest Press Release!!

We have reported that PIP-Based KRAS inhibitor KR12 exhibits excellent tumor accumulation properties. We evaluated PIP portion of KR12 for its tumor accumulation capability using the CAM assay, a simple and versatile chicken egg tumor model. As a result, we have shown that the PIP contained in KR12 exhibits remarkable tumor accumulation and localizes near the nucleus. KR12 also inhibit tumor growth in the CAM model. Thus, it is expected that new KRAS inhibitors will be developed and the CAM assay will be useful for evaluation of tumor accumulation.

KRAS阻害剤として開発されたKR12 に含まれたピロールイミダゾールポリアミド(PIP)の強い腫瘍蓄積に関する研究成果を発表しました。



Higashi, Y., Ikeda, S., Matsumoto, K., Satoh, S., Komatsu, A., Sugiyama, H. and Tamanoi, F. (2022) Tumor Accumulation of PIP-Based KRAS Inhibitor KR12 Evaluated by the Use of a Simple, Versatile Chicken Egg Tumor Model. Cancers 2022, 14, 951. doi: 10.3390/cancers14040951

Members presented their research at various conferences and lectures.

・7/24 "Solgel2022" Ms. Mathilde

・8/22 Fujita Health University Prof. Tamanoi

・10/29 "The 18th Congress on Neutron Capture Therapy" Mr. Matsumoto

・11/7 Japan Reagent Association Prof. Tamanoi

・11/16-18 "The academic conference on the patient-derived model" Prof. Tamanoi, Ms. Komatsu

・12/6-8 "15th International Symposium on Nanomedicine (ISMN2022)" Prof. Tamanoi

You can check the article from here.


・7/24 "Solgel2022" マチルダさん

・8/22 藤田医科大学 玉野井先生

・10/29 日本中性子捕捉療法学会 松本さん

・11/7 日本試薬協会 玉野井先生

・11/16-18 日本患者由来がんモデル学会 玉野井先生、小松さん

・12/6-8 "15th International Symposium on Nanomedicine (ISMN2022)" 玉野井先生


▼Mesoporous Silica Nanoparticles (MSN) : 130 nm in diameter, 1400 pores/particle


▼Biodegradable Periodic Mesoporous Organosilica (BPMO)


▼Our recent publication relating to this topic


Harutaka Mekaru, Akitaka Yoshigoe, Michihiro Nakamura, Tomohiro Doura, and Fuyuhiko Tamanoi.(2019)Biodegradability of Disulfide-Organosilica Nanoparticles Evaluated by Soft X‐ray Photoelectron Spectroscopy: Cancer Therapy Implications, ACS Applied Nano Materials, Vol.2, Iss.1, 479-488, 2019 DOI : 10.1021/acsanm.8b02023

▼The chicken egg tumor model


▼Patient derived tumor model


▼Collaborating with Prof. Muto


武藤研究室ホームページWebsite of Muto Lab. (only in Japanese)

▼Boron Neutron Capture Therapy(BNCT)


▼Experiment room


▼Making MSN Place